Eisai To Manufacture Breast Cancer Drug In Europe
This article was originally published in PharmAsia News
Executive SummaryEisai announced June 26 a ¥5 billion additional investment to European Knowledge Center in Hatfield, a suburb of London. The company completed and opened the facility the same day. Eisai plans to manufacture breast cancer drug E7389 starting in 2011. Currently under Phase II trials in Japan and Phase III trials in the U.S. and Europe, Eisai aims for a 2010 NDA submission. Eisai previously invested ¥160 million to the center; the production line has an annual capacity of 400 million tablets. Positioned as a global strategic product for Eisai, E7389 is estimated to become a ¥100 billion blockbuster drug. (Click here for more - Japanese language
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.